Physician profile
Tod A Aust
NPI 1609191212
$10,563.64
in general payments reported to CMS, 2019-2025
40 companies · $292 in 2025
The $292 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,497 · 2020: $5,930 · 2021: $248 · 2022: $209 · 2023: $231 · 2024: $157 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $679.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Flowonix Medical Incorporated | $6,346.52 | 2019-2020 | |
| Abbott Laboratories | $2,003.71 | 2019-2024 | Proclaim, Eterna |
| Boston Scientific Corporation | $601.74 | 2019-2025 | Intracept, Spectra Wavewriter |
| Biotronik Nro, INC. | $144.50 | 2025 | Prospera |
| Carbofix Spine INC | $141.61 | 2019 | |
| Stryker Corporation | $125.00 | 2019 | |
| Painteq LLC | $120.33 | 2021 | |
| Stimwave Technologies Incorporated | $77.50 | 2022 | |
| Virtus Pharmaceuticals LLC | $75.51 | 2023-2025 | Levorphanol Tartrate |
| Saluda Medical Americas, INC. | $74.44 | 2025 | Evoke |
| Arbor Pharmaceuticals, INC. | $58.11 | 2019 | |
| Si-Bone, INC. | $56.23 | 2023 | |
| Tersera Therapeutics LLC | $53.07 | 2019-2020 | |
| Nevro Corp. | $52.35 | 2019-2024 | Senza |
| Avanos Medical | $47.35 | 2019 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tod Aust listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.